Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIAMI, AUG. 13, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

LONGEVERON ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MIAMI, AUG. 11, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) (LONGEVERON OR COMPANY), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF 5,882,354 OF THE COMPANY'S CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), TOGETHER WITH SHORT-TERM WARRANTS TO PURCHASE UP TO 14,705,885 SHARES OF CLASS A COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.85 PER SHARE OF CLASS A COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING SHORT-TERM WARRANTS. THE SHORT-TERM WARRANTS HAVE AN EXERCISE PRICE OF $0.85 PER SHARE AND ARE IMMEDIATELY EXERCISABLE UPON ISSUANCE FOR A PERIOD OF TWENTY-FOUR MONTHS FOLLOWING THE DATE OF ISSUANCE.

LONGEVERON ANNOUNCES CLOSING OF UP TO $17.5 MILLION PUBLIC OFFERING

MIAMI, AUG. 08, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) (LONGEVERON OR COMPANY), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THE PRICING OF A PUBLIC OFFERING OF 5,882,354 OF THE COMPANY'S CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), TOGETHER WITH SHORT-TERM WARRANTS TO PURCHASE UP TO 14,705,885 SHARES OF CLASS A COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.85 PER SHARE OF CLASS A COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING SHORT-TERM WARRANTS. THE SHORT-TERM WARRANTS WILL HAVE AN EXERCISE PRICE OF $0.85 PER SHARE AND WILL BE IMMEDIATELY EXERCISABLE UPON ISSUANCE FOR A PERIOD OF TWENTY-FOUR MONTHS FOLLOWING THE DATE OF ISSUANCE.

LONGEVERON ANNOUNCES UP TO $17.5 MILLION PUBLIC OFFERING

MIAMI, AUG. 05, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON WEDNESDAY, AUGUST 13, 2025 AFTER THE U.S. FINANCIAL MARKETS CLOSE. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST THE SAME DAY AT 4:30 P.M.

LONGEVERON TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 13, 2025

LONGEVERON HAS LICENSED ISSUED US PATENT 12,168,028 B2 , ENTITLED METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS FROM THE UNIVERSITY OF MIAMI NEW PATENT PROTECTS A METHOD TO DERIVE GHRH-RECEPTOR+ CARDIOMYOGENIC CELLS FROM PLURIPOTENT STEM CELLS (PSCS) NEW TECHNOLOGY SUBSTANTIALLY ADVANCES LONGEVERON'S REPERTOIRE OF STEM CELL THERAPY TECHNOLOGIES OPPORTUNITY TO EXPAND PIPELINE IN CARDIOVASCULAR, RARE AND PEDIATRIC DISEASE AREAS MIAMI, JULY 21, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC, AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT HAS LICENSED AN ISSUED US PATENT (12,168,028 B2) FOR A STEM CELL TECHNOLOGY FROM THE UNIVERSITY OF MIAMI. THE COMPOSITION OF MATTER PATENT PROTECTS UNIQUE INDUCED PLURIPOTENT DERIVED CARDIOMYOGENIC CELLS THAT HAVE WIDESPREAD THERAPEUTIC INDICATIONS FOR HEART DISEASES.

LONGEVERON ANNOUNCES LICENSING OF NEW CARDIAC SELECTIVE INDUCED PLURIPOTENT STEM CELL TECHNOLOGY FOR CARDIOVASCULAR DISEASE

FDA APPROVES LONGEVERON'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR STEM CELL THERAPY AS A POTENTIAL TREATMENT FOR PEDIATRIC DILATED CARDIOMYOPATHY.

LONGEVERON ANNOUNCES U.S. FDA APPROVAL OF IND APPLICATION FOR A PHASE 2 PIVOTAL REGISTRATION STUDY EVALUATING LAROMESTROCEL AS A TREATMENT OF PEDIATRIC DILATED CARDIOMYOPATHY (DCM)

MR. POWELL TO OVERSEE LONGEVERON'S PARTNERING AND INTERNATIONAL STRATEGY EFFORTS MIAMI, JUNE 26, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT HAS APPOINTED THAN POWELL AS CHIEF BUSINESS OFFICER, EFFECTIVE JULY 7, 2025. IN THIS ROLE, HE WILL LEAD THE COMPANY'S OVERALL BUSINESS STRATEGY, ALZHEIMER'S DISEASE PROGRAM PARTNERING EFFORTS, AND INTERNATIONAL STRATEGY FOR THE HYPOPLASTIC LEFT HEART SYNDROME (HLHS) PROGRAM.

LONGEVERON APPOINTS THAN POWELL AS CHIEF BUSINESS OFFICER

LONGEVERON COMPLETES ENROLLMENT OF PIVOTAL PHASE 2B CLINICAL TRIAL EVALUATING LAROMESTROCEL AS A TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS).

LONGEVERON ANNOUNCES COMPLETION OF ENROLLMENT OF PIVOTAL PHASE 2B CLINICAL TRIAL EVALUATING LAROMESTROCEL AS A TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

MIAMI, JUNE 09, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT WA'EL HASHAD, CEO, WILL PRESENT AT THE H.C. WAINWRIGHT 6TH ANNUAL NEURO PERSPECTIVES HYBRID CONFERENCE, TAKING PLACE JUNE 16-17, 2025.

LONGEVERON TO PARTICIPATE IN THE H.C. WAINWRIGHT 6TH ANNUAL NEURO PERSPECTIVES HYBRID CONFERENCE

LONGEVERON TO HOST ALZHEIMER'S DISEASE PROGRAM PARTNERING MEETINGS AT BIO 2025 CONFERENCE JUNE 16-19. POSITIVE PHASE 2A DATA PUBLISHED IN NATURE MEDICINE.

LONGEVERON TO ATTEND BIO INTERNATIONAL CONVENTION 2025

LONGEVERON SELECTED AS A TOP 40 SEMIFINALIST BASED ON THE FEASIBILITY OF ITS STEM CELL THERAPY STEM CELL THERAPY LAROMESTORCEL BEING EVALUATED AS POTENTIAL TREATMENT FOR ALZHEIMER'S DISEASE AND HLHS, A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION MIAMI, MAY 12, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT HAS BEEN SELECTED AS A SEMI-FINALIST TEAM AND ONE OF THE TOP 40 TEAMS RECEIVING A $250,000 MILESTONE 1 AWARD IN THE XPRIZE HEALTHSPAN COMPETITION. WE'RE PROUD TO BE A SEMIFINALIST TEAM OF XPRIZE HEALTHSPAN, A 7-YEAR, $101 MILLION GLOBAL COMPETITION THAT AIMS TO REVOLUTIONIZE THE WAY WE APPROACH HUMAN AGING, SAID WA'EL HASHAD , CHIEF EXECUTIVE OFFICER OF LONGEVERON.

LONGEVERON NAMED XPRIZE HEALTHSPAN SEMIFINALIST AND TOP 40 MILESTONE 1 AWARD RECIPIENT

LONGEVERON ANNOUNCES Q1 2025 FINANCIAL RESULTS & PROVIDES BUSINESS UPDATE. PIVOTAL PHASE 2 CLINICAL TRIAL ACHIEVES 95% ENROLLMENT. EXPECTED FULL ENROLL Q2.

Longeveron Inc.

LGVN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Longeveron Inc.

LGVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LGVN